Gossamer Bio(GOSS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update - $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - SAN DIEGO—(BUSINESS WIRE)— August 12, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-IL ...